Strengthening tuberculosis (TB) prevention, diagnosis, and treatment in Southeast Asia to end TB

The Centers for Disease Control and Prevention, through its Global Health Center, has announced a forecasted funding opportunity under the U.S. Department of Health and Human Services titled Strengthening tuberculosis (TB) prevention, diagnosis, and treatment in Southeast Asia to end TB. This cooperative agreement program is anticipated to launch in December 2025 with applications due in February 2026. The Notice of Funding Opportunity is focused on addressing the burden of tuberculosis in high-prevalence regions of Southeast Asia by supporting projects that advance prevention, early diagnosis, and effective treatment strategies. This initiative reflects CDC’s longstanding role in global infectious disease control and its specific mandate to develop and implement innovative evidence-based approaches to combat tuberculosis. The funding scope centers on reducing TB burden and mortality through three primary intervention areas. First, the program supports expansion of early TB diagnosis, including among asymptomatic individuals, by encouraging active case finding, deploying advanced screening methods, and scaling up novel diagnostic technologies. Second, the initiative aims to expand TB preventive treatment for at-risk populations, conduct readiness assessments for the introduction of new TB vaccines, and enhance infection prevention and control capacity. Third, the program focuses on improving treatment outcomes for both TB and drug-resistant TB through the implementation of novel and shorter regimens designed to improve patient outcomes and program efficiency. The opportunity is forecasted to provide an approximate total of $10 million for the first year, pending availability of funds. The award ceiling and floor are listed as zero in the initial forecast, indicating that exact award levels will be clarified in the final announcement. CDC anticipates issuing up to two awards under this competition. As a cooperative agreement, this program will involve substantial engagement between awardees and CDC, ensuring alignment with global TB control strategies and monitoring for effective implementation. Eligibility for this program is broad, allowing participation from a wide range of entities. Eligible applicants include state, county, city, and township governments; special district governments; public housing authorities; independent school districts; tribal governments and organizations; public and private higher education institutions; nonprofits with or without 501(c)(3) status; for-profit organizations including small businesses; and other specified entities. The opportunity is therefore open to a diverse pool of stakeholders, reflecting the complexity and multidisciplinary requirements of TB control efforts. Unrestricted eligibility applies, provided applicants meet the general requirements of federal cooperative agreements. Applications will be submitted electronically, with a forecasted due date of February 17, 2026 at 11:59 pm Eastern Time. The estimated award date and project start date are September 30, 2026. The notice was first forecasted on October 1, 2025 and will remain active until March 19, 2026, after which it will be archived. No pre-application deadlines such as letters of intent are specified in the current forecast, though applicants should monitor for updates in the final posting. Contact for the program is listed as DGHT NOFOs, with email correspondence directed to pepfarfoas@cdc.gov. No phone number has been provided. Additional program information, including application requirements and supporting documentation, will be released with the final announcement. Interested applicants are advised to review CDC’s Global TB program materials and prepare for anticipated requirements in financial, programmatic, and technical capacities.